View More Recent Stories

Oct 6, 2022 08:00AM Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
Sep 12, 2022 05:37AM Edgewise Therapeutics (EWTX) Reports Positive 4-Month Interim Data of EDG-5506
Sep 11, 2022 05:00PM Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
Sep 7, 2022 08:01AM Edgewise Therapeutics Inc. (EWTX) Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy
Sep 7, 2022 08:00AM Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Aug 4, 2022 08:00AM Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
Aug 3, 2022 08:00AM Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
Jul 12, 2022 08:00AM Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
Jun 20, 2022 08:00AM Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
Jun 16, 2022 08:00AM New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeleta
May 31, 2022 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 11, 2022 08:00AM Edgewise Therapeutics Reports First Quarter 2022 Financial Results
May 3, 2022 08:00AM Edgewise Therapeutics to Present at Upcoming Investor Conferences
Apr 14, 2022 08:00AM Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
Mar 8, 2022 08:00AM Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
Feb 24, 2022 08:00AM Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 2, 2022 09:00AM Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
Jan 5, 2022 08:08AM Edgewise Therapeutics Inc. (EWTX) Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy
Jan 5, 2022 08:00AM Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
Dec 15, 2021 09:00AM Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
Nov 17, 2021 09:00AM Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2
Nov 10, 2021 08:00AM Edgewise Therapeutics Reports Third Quarter 2021 Financial Results
Oct 28, 2021 06:00AM Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patie
Sep 14, 2021 09:00AM Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23
Aug 16, 2021 09:01AM Edgewise Therapeutics Inc. (EWTX) Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy
Aug 16, 2021 09:00AM Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)
Aug 9, 2021 09:00AM Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
Aug 4, 2021 09:00AM Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
View More Recent Stories